Artisan Partners Limited Partnership Buys 107,292 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Artisan Partners Limited Partnership increased its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 27.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 499,134 shares of the biopharmaceutical company’s stock after purchasing an additional 107,292 shares during the period. Artisan Partners Limited Partnership’s holdings in Agios Pharmaceuticals were worth $16,402,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of AGIO. KBC Group NV lifted its stake in shares of Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 611 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Agios Pharmaceuticals by 6.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company’s stock valued at $539,000 after acquiring an additional 688 shares in the last quarter. Atria Investments Inc boosted its stake in Agios Pharmaceuticals by 6.9% during the 4th quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company’s stock valued at $373,000 after purchasing an additional 737 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in Agios Pharmaceuticals during the 4th quarter worth approximately $33,000. Finally, Swiss National Bank raised its stake in shares of Agios Pharmaceuticals by 1.0% in the fourth quarter. Swiss National Bank now owns 100,760 shares of the biopharmaceutical company’s stock worth $3,311,000 after purchasing an additional 1,000 shares during the last quarter.

Insider Activity at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares in the company, valued at $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.93% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. HC Wainwright assumed coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They set a “buy” rating and a $58.00 price target for the company. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Royal Bank of Canada increased their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Scotiabank boosted their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $56.57.

Agios Pharmaceuticals Stock Down 1.8 %

Shares of AGIO stock opened at $30.28 on Friday. The firm has a market cap of $1.73 billion, a P/E ratio of 2.67 and a beta of 0.90. The company has a 50 day moving average of $33.17 and a 200-day moving average of $40.87. Agios Pharmaceuticals, Inc. has a 12-month low of $27.14 and a 12-month high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, equities analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.